PK of Serelaxin in Severe Renal Impairment and ESRD
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The study is designed to evaluate the pharmacokinetics, safety and tolerability,
immunogenicity and pharmacogenetics of a single dose of serelaxin/RLX030 in patients with
severe renal impairment and end-stage-renal-disease (ESRD) compared to healthy volunteers.